Alkem Laboratories (ALKEM) Q3 24/25 earnings summary

Executive summary

• Focus on higher-margin offerings, cost-saving strategies, and portfolio enhancement led to improved EBITDA margins and sustainable growth initiatives.

• Q3FY25 revenue from operations grew 1.5% YoY to ₹33,743 million; 9MFY25 revenue up 0.9% YoY to ₹98,208 million.

• Two acquisitions announced: Adroid (dermato-cosmetology, INR 140 crores) and Bombay Ortho (orthopedic implants, INR 147 crores), expanding presence in value and premium medical device segments.

• Standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2024, were reviewed and approved, with auditors issuing unmodified review reports for both.

• Strategic emphasis on flagship brands and new launches, including GLP-1 (semaglutide), to drive future growth.

Financial highlights

• Q3 FY25 revenue: INR 33,743 million, up 1.5% YOY; nine-month revenue: INR 98,208 million, up 0.9% YOY.

• Q3 EBITDA: INR 7,594 million (22.5% margin), up 7.3% YOY; nine-month EBITDA: INR 21,209 million (21.6% margin), up 15% YOY.

• Q3 net profit: INR 6,258 million, up 5.2% YOY; nine-month net profit: INR 18,596 million, up 23.8% YOY.

• Q3FY25 gross profit rose 7.5% YoY to ₹21,700 million; gross margin at 64.3%.

• Interim dividend of ₹37 per equity share declared for FY25.

Outlook and guidance

• FY25 EBITDA margin guidance maintained at 19%, with Q4 expected to be seasonally weaker due to higher R&D and filing expenses.

• Domestic business expected to grow in line with IPM at ~7% for FY25, with Q4 growth anticipated at 9.5-10%.

• Non-US international business expected to stabilize and improve in Q4 after Chile-related headwinds.

• Ongoing R&D investments, with R&D expenses at 3.9% of Q3FY25 revenue and 4.1% of 9MFY25 revenue.

• The transfer of the Generic Business is in process, with the Business Transfer Agreement being executed.